Niraparib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-NIRAPARIB |
|---|---|
| Type | Drug |
| Aliases | Akeega (with abiraterone)ZejulaНірапариб |
| Status | pending_clinical_signoff |
| Diseases | DIS-OVARIAN |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | PARP inhibitor |
|---|---|
| Mechanism | PARP1/2 inhibitor with mCRPC indication in combination with abiraterone for BRCA-mutant disease (MAGNITUDE trial). Akeega is the fixed-dose combination tablet with abiraterone. |
| Typical dosing | Akeega combination: niraparib 200 mg + abiraterone 1000 mg PO daily + prednisone 10 mg daily. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
BRCA-mutant mCRPC option; thrombocytopenia management more demanding than olaparib. UA-access barrier.
Used By
Regimens
REG-NIRAPARIB-MAINT-OVARIAN- Niraparib maintenance (HRD+ recurrent platinum-sensitive ovarian, NOVA / PRIMA)